Mahmoudi F and Hedadji M
Oran University, Algeria
Posters & Accepted Abstracts: J Food Process Technol
The B. bifidum strain (Bf1) was isolated on MRS medium contended 0.5 g/L of cysteine hydrochloride, 2 mg/L of nalidixic acid and 0.1 mg of mupirocin. This strain was isolated from (breastfed infant faeces). The effectiveness of Bifidobacterium bidum Bf 1 as a probiotic against enterohemorrhagic Escherichia coli O157:H7 infection was studied using rats model. Rats were fed with the probiotic for 7 days before or after single challenge with E. coli O157:H7. Fecal B. bifidum Bf1 and E. coli O157:H7 counts obtained by selective culturing methods were assessed for 1 week before and after infection while feed intake, body weight and composition were monitored during 1 week after infection. Histology of gut tissue (intestine) was analyzed until 1 and 2 weeks post infection, respectively. The pathogenicity of E. coli O157:H7, marked by body weight loss and intestinal histopathological changes in the infected group, was significantly reduced in the B. bifidum-treated group. Feeding B. bifidum Bf1 for 7 days before infection resulted in greater post-challenge feed intake and weight gain and lower fecal levels of E. coli O157:H7. A lesser degree of protection against E. coli O157:H7 infection was observed when Bifidobacteria were given during the 7 days after E. coli O157:H7 infection. These results demonstrate that feeding the probiotic B. bifidum Bf1 to rat can reduce the severity of E. coli O157:H7 infection, and suggest that this strain represents a good candidate for the prevention of enteric infections in human.
Mahmoudi F is a Ph D Student in Oran University, Algeria.
Email: [email protected]